TESARO (TSRO) Issues Encouraging Update for Niraparib Phase 1 in Ovarian Cancer
Tweet Send to a Friend
TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
